Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.23)
# 616
Out of 5,081 analysts
23
Total ratings
52.17%
Success rate
20.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $17 → $16 | $3.95 | +305.06% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $3.96 | +127.27% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $29.96 | -56.61% | 3 | Nov 12, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $71.58 | -13.38% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.59 | +404.54% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.64 | +371.33% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $3.32 | +80.72% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $8.28 | +93.24% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $10.06 | +188.27% | 1 | Dec 5, 2024 |
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $3.95
Upside: +305.06%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.96
Upside: +127.27%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $29.96
Upside: -56.61%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $71.58
Upside: -13.38%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.59
Upside: +404.54%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.64
Upside: +371.33%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $3.32
Upside: +80.72%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $8.28
Upside: +93.24%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $10.06
Upside: +188.27%